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Abstract: As described elsewhere in this Special Issue on biomarkers, much progress has been made
in the detection of modified DNA within organisms at endogenous and exogenous levels of exposure
to chemical species, including putative carcinogens and chemotherapeutic agents. Advances in the
detection of damaged or unnatural bases have been able to provide correlations to support or refute
hypotheses between the level of exposure to oxidative, alkylative, and other stresses, and the resulting
DNA damage (lesion formation). However, such stresses can form a plethora of modified nucleobases,
and it is therefore difficult to determine the individual contribution of a particular modification to
alter a cell’s genetic fate, as measured in the form of toxicity by stalled replication past the damage, by
subsequent mutation, and by lesion repair. Chemical incorporation of a modification at a specific site
within a vector (site-specific mutagenesis) has been a useful tool to deconvolute what types of damage
quantified in biologically relevant systems may lead to toxicity and/or mutagenicity, thereby allowing
researchers to focus on the most relevant biomarkers that may impact human health. Here, we will
review a sampling of the DNA modifications that have been studied by shuttle vector techniques.
Keywords: DNA lesion; DNA damage; shuttle vector technique; replication block; mutagenicity;
mutational spectrum; mutational signature; DNA repair; DNA adduct bypass; site-specific mutagenesis
1. Introduction
The human genome is constantly exposed to and damaged by endogenous chemicals, such as
reactive oxygen species, lipid peroxidation intermediates, and alkylating agents. These electrophilic
reactive chemicals, as well as environmental carcinogens and administered drugs, are known to
generate various DNA adducts [1–3]. Some of the adducts block DNA replication or cause mutations
and have been used as biomarkers to monitor the level of DNA damage or of disease progression [4–6].
One of the major goals for researchers is to understand the deleterious consequences of those
lesions within the cell or animal. Among the different methods for studying the biological effects
of the adducts, use of shuttle vectors containing a chemically defined lesion at a specific site has
provided information about the biological and toxicological properties of the adduct [4,7]. The shuttle
vector-based methods normally involve the steps outlined in Figure 1. Oligonucleotide synthesis: An
oligonucleotide (oligo) containing a structurally defined lesion at a specific site is made either through
a biomimetic route (in situ formation by direct chemical reaction, followed by HPLC purification
of site-specifically modified oligo), or purely synthetically using a normal or convertible nucleoside
phosphoramidite, etc. Vector construction: An ss- or ds-DNA vector containing the modified oligo is
built by cutting the parent vector with one or a pair of restriction endonuclease(s), followed by ligation
of the 5′-phosphorylated modified oligo. Cellular processing: The vector is transfected into different
types of cells (e.g., Escherichia. coli (E. coli) or mammalian), and cellular polymerases are allowed
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to replicate or transcriptionally bypass the lesion under different repair or bypass conditions. Data
analysis: DNA is extracted, amplified using PCR, and the biological outcomes are analyzed, which
include the ability of the lesion/adduct to block polymerases or cause a mutation when processed by a
polymerase during cellular replication. This assessment could be done by plaque or colony counting
and picking with Sanger sequencing, 32P-post labeling and thin-layer chromatography (TLC), liquid
chromatography-mass spectrometry (LC-MS), next-generation sequencing (NGS), etc. [4,5,7–9]. The
shuttle vector-based method was initially introduced by Essigmann [7,9–11], further developed and
utilized by Wang [4,5], Moriya [12,13], Livneh [14,15], Greenberg [16,17], Basu [18,19], Lloyd [20,21],
Loechler [22,23], Fuchs [24,25], Pagès [26,27], and others. Several informative review articles have been
written by these authors on designing and applying the methods.
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Figure 1. Schematic overview of the shuttle vector-based methods for evaluating DNA biomarkers.
In this work, we will review a variety of DNA biomarkers or probes that have been studied using
the shuttle vector techniques and briefly summarize their biological outcomes. In all cases, focus is
placed on the effect of the lesion to block replication and to cause mutations. For the details regarding
the formation of DNA damage and other properties of the lesions, please refer to the original literature
or review articles. We apologize in advance to researchers whose work we could not include in this
review. After detailed discussions on individual lesions, we will provide some perspectives on possible
future directions.
2. Discussions on Individual Modifications
Below, we will cover modified DNA structures generated from oxidative stress, alkylation, and
other processes (Figures 2–5). In the following sections, the biological effects of a certain lesion are
briefly summarized. Please see Figures 2–5 for chemical structures and Table 1 for detailed information.
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Table 1. Bypass efficiency and mutagenicity of DNA modifications.
Oxidative Lesion Bypass Efficiency Mutation Cell
8-oxo-G
88% [28,29] G>T 3% (44%, MutY-) [28,29] E. coli
G>T 8% [30] Human
Fapy-dG 31–43% (TXN sequences) [31] G>T 1.2–1.9% (0.7–2.1%, MutM-/MutY-) [31] E. coli
G>T 10% [30] Human
NI 7% (57%, SOS) [32] G>C 8.9%, G>A 19%, G>T 22% (G>C 2.5%, G>A13%, G>T, 18%, SOS) [32] E. coli
Oa 52% [28], 51% [33], 108% (118%MutY-) [29]
G>T 97% [28], 99% [33], 97% (no change, MutY-)
[29] E. coli
Oz 57% [28] G>T 86% [28] E. coli
Ca 65% [28] G>T 95% [28] E. coli
Gh 75% [34], 20% (30% MutY-) [29] G>C 98%, G>T 2% [34], G>T 40%, G>C 57%, G>A3% (no change, MutY-) [29] E. coli
Sp1 9% [34], 19% (38%, MutY-) [29] G>C 72%, G>T 27% [34], G>T 78%, G>C 19%, G>A1% (no change, MutY-) [29] E. coli
Sp2 9% [34], 17% (30%, MutY-) [29] G>C 57%, G>T 41% [34], G>T 49%, G>C 48%, G>A3% (no change, MutY-) [29] E. coli
Ur 11% [35], 10% (10% MutY-) [29] G>T 99% [35], G>T 54%, G>C 35%, G>A 9% (nochange, MutY-) [29] E. coli
Iz 60% (71%, SOS) [32] G>C 88%, G>A 2%, G>T 1.1% (G>C 75%, G>A3.4%, G>T 5.5%, SOS) [32] E. coli
Cyclo-dG 11% (6% pol V-) [36] G>A 20% [36] E.coli
S-cdG 4% [37] G>T 35%, G>A 20% [37] Human
Cyclo-dA 31% (13% pol V-) [36] A>T 11% [36] E. coli
S-cdA 6% [37] A>T 12% [37] Human
Tg 96% [38] E. coli
5ClC 75% (75% AlkB-) [39] C>T 5% (same in AlkB-) [39] E. coli
5-OH-C C>T 0.05%, C>G 0.001% [40] E. coli
5-OH-U C>T 83% [40] E. coli
Ug C>T 80% [40] E. coli
THF AP site 6% [28], 5.8% [32], 4% (4%MutY-) [29]
AP>T 50%, AP>C 26%, AP>A 7%, -1 del 13% (no
change, MutY-) [29] E. coli
2-deoxyribonolactone 5%, (3% pol II-), (1% pol V-) [41] T 35%, C 42%, A 12%, G 8%, 5
′ T (T 42%, C 38%, A
6%, G 14%, 5′ C) [41] E. coli
Alkyl Modification Bypass Efficiency Mutation Cell
m1G 15% (3%, AlkB-) [9], 20% (2%,AlkB-) [33]
G>T 3% (G>T 57%, G>A 17%, G>C 6%, AlkB-) [9],
G>T 4%, G>A 2% (G>T 52%, G>A 20%, G>C 4%,
AlkB-) [33]
E. coli
m2G 90% (84% AlkB-; 98% DinB-; 96%AlkB- and DinB-) [42]
G>A 3% (2.7%, AlkB-; 3%, DinB-; 3%, AlkB- and
DinB-) [42] E. coli
e2G 100% (98% AlkB-), (106% DinB-),(99% AlkB- and DinB-) [42]
G>A 2%, G>C 1% (G>A 2.3%, AlkB-), (G>A 2%,
AlkB- and DinB-) [42] E. coli
N2-CMdG 100% [43] Not mutagenic [43] Mouse
R-N2-CEdG
39% (13% pol V-) [44] Not mutagenic [44] E. coli
100% [43] Not mutagenic (G>A 23%, G>T 15%, pol κ-) [43] Mouse
S-N2-CEdG
75% (28% pol V-) [44] Not mutagenic [44] E. coli
99% [43] Not mutagenic (G>A 23%, G>T 15%, pol κ-) [43] Mouse
FF 101% (100% AlkB-), (28% DinB-),(36% AlkB- and DinB-) [42] G>C 1%, (G>A 1%, G>T 1%, AlkB-DinB-) [42] E. coli
HF 92% (88% AlkB-), (28% DinB-),(40% AlkB- and DinB-) [42] G>C 2% [42] E. coli
O6mG G>A 99% [45,46] E. coli
O6-POB-dG 70% [47] G>A 90%, G>T 2.5% [47] E. coli
O6-PHB-dG 40% [47] G>A 95% [47] E. coli
O6-CM-dG
10% [47] G>A 10% [47] E. coli
40% [48] G>A 6% [48] Human
O6-ACM-dG 2% [47] G>A 30% [47] E. coli
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Table 1. Cont.
Alkyl Modification Bypass Efficiency Mutation Cell
O6-HOEt-dG 15% [47] G>A 40% [47] E. coli
PdG 25% [12] G>T 6% [12] Human
α-OH-PdG 17% [12] G>T 11% [12] Human
γ-OH-PdG 73% [12] Not mutagenic [12] Human
1,N2-eG
4% (2% AlkB-) (1.8%
AlkB-DinB-) [8]
G>A 6%, G>T 6%, G>C 2%, −1/2 del 5% (G>A 13%,
G>T 13%, G>C 1%, −1/2 del 9%, AlkB-), (same in
AlkB-DinB-) [8]
E. coli
2′-F-N2,3-eG 21% (26% AlkB-) (14%AlkB-DinB-) [8] G>A 30% (30% AlkB-), (30% AlkB-DinB-) [8] E. coli
m1A 100% (12%, AlkB-) [9] A>T 0.06% (0.61%, AlkB-) [9] E. coli
eA
85% (5% AlkB-) [33], 130% (9%
AlkB-) [49]
<0.5% (A>T 25%, A>G 5%, A>C 5%, AlkB-) [33],
A>C 1%, A>T 1% (A>T 22%, A>C 8%, A>G 7%,
AlkB-) [49]
E. coli
17% [50] Human
EA 135% (14% AlkB-) [49] A>C 1%, A>G 0.5%, A>T 0.5% (A>C 2%, A>G 1%,A>T 1%, AlkB-) [49] E. coli
N6-CMdA
98% [36] Not mutagenic [36] E. coli
65% (35% pol k-) [48] Not mutagenic [48] Human
S-N6-HB-dA 120% [51] Not mutagenic [51] E. coli
R,R-N6,N6-DHB-dA 100% [51] <1% [51] E. coli
S,S-N6,N6-DHB-dA 60% [51] A>G 1% [51] E. coli
R,S-1,N6-γ-HMHP-dA 10% [51] A>T 2% [51] E. coli
O2-MedT
60% [52], 55% [53] T>A 1%, T>G 1% [52], T>A 56% [53] Human
5% [54] T>A 10%, T>G 10% [54] E. coli
O2-EtdT
21% (5% pol V-) [55] T>C 35%, T>A 15%, T>G 5% (T>C 10%, pol V-) [55] E. coli
45% [52] T>A 5%, T>G 3% [52] Human
O2-nPrdT 35% [52] T>A 12%, T>G 5% [52] Human
O2-iPrdT 35% [52] T>A 4%, T>G 1% [52] Human
O2-nBudT 30% [52] T>A 13%, T>G 6% [52] Human
O2-iBudT 15% [52] T>A 4%, T>G 2% [52] Human
O2-sBudT 15% [52] T>A 4%, T>G 2% [52] Human
O2-POB-dT
3% [54] 12% T>A, 38% T>G [54] E. coli
26% [53] T>A 47% [53] Human
m3T 6%, (4% AlkB-) [9] T>A 32%, T>C 6%, T>G 2% (T>A 47%, T>C 9%,T>G 2%, AlkB-) [9] E. coli
N3-EtdT 17% (3% pol V-) [55] T>C 15%, T>A 21%, T>G 3% (Not mutagenic, polV-) [55] E. coli
N3-CMdT
55% [36] T>A 66% [36] E. coli
40% [48] T>A 81% [48] Human
O4-CMdT
49% [36] T>C 86% [36] E. coli
40% [48] T>C 68% (25% pol ζ-) [48] Human
O4-MedT 32% [56] T>C 58% [56] Human
O4-EtdT
76% [55] T>C 84% (Not mutagenic, pol V-) [55] E. coli
33% [56] T>C 82% [56] Human
O4-nPrdT 35% [56] T>C 42% [56] Human
O4-iPrdT 30% [56] T>C 44% [56] Human
O4-nBudT 32% [56] T>C 29% [56] Human
O4-iBudT 24% [56] T>C 42% [56] Human
O4-R-sBudT 20% [56] T>C 25% [56] Human
O4-S-sBudT 22% [56] T>C 25% [56] Human
m3C
100% (10% AlkB-) [9], 113% (14%
AlkB-) [57], 98% (5% AlkB-; 115%
DinB-; 7.5% AlkB-DinB-) [42],
100% (15% AlkB-) [39]
C>T 1% (C>T 14%, C>A 14%, C>G 2%, AlkB-) [9],
Not mutagenic (C>T 55%, C>A 30%, C>G 1%,
AlkB-) [57], Not mutagenic (C>T 41%, C>A 41%,
C>G 4%, AlkB-) [42], Not mutagenic (C>T 52%,
C>A 30%, AlkB-) [39]
E. coli
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Table 1. Cont.
Alkyl Modification Bypass Efficiency Mutation Cell
e3C 96%, (9% AlkB-) [9] Not mutagenic (C>T 17%, C>A 11%, C>G 2%,AlkB-) [9] E. coli
N4-CMdC
83% [36] Not mutagenic [36] E. coli
80% [48] Not mutagenic [48] Human
5mC
100% (100% AlkB-) [39] Not mutagenic (same in AlkB-) [39] E. coli
100% [58] Not mutagenic [58] Human
5hmC
100% [59] Not mutagenic [59] E. coli
98% [58] Not mutagenic [58] Human
5fC
100% [59] Not mutagenic [59] E. coli
74% [58] Not mutagenic [58] Human
5caC
100% [59] Not mutagenic [59] E. coli
72% [58] Not mutagenic [58] Human
eC 24% (13% AlkB-) [33] C>A 24%, C>T 11% (C>A 49%, C>T 31%, AlkB-)[33] E. coli
H-edC
1% [50] C>G 40% [50] E. coli
10% [50] C>A 60%, C>T 32% [50] Human
5hmU 80% [60] Not mutagenic [60] Human
Sp-Me-PTE 110% (Ada-, decreases from140% to 70%) [61] TT>GT 50%, TT>GC 15% [61] E. coli
Rp-Me-PTE 30% [61] Not mutagenic [61] E. coli
Sp-Et-PTE 190% [61] Not mutagenic [61] E. coli
Rp-Et-PTE 40% [61] Not mutagenic [61] E. coli
Sp-nPr-PTE 160% [61] Not mutagenic [61] E. coli
Rp-nPr-PTE 70% [61] Not mutagenic [61] E. coli
Sp-nBu-PTE 100% [61] Not mutagenic [61] E. coli
Bulky Lesion Bypass Efficiency Mutation Cell
N2-MC-dG 38% [62] G>T 18% [62] Human
N2-2,7-DAM-dG 27% [62] G>T 10% [62] Human
AL-II-dG 9% [63] G>T 9% [63] Mouse
AFB1-N7-dG G>T 1.5% [64] E. coli
AFB1-FAPY G>T 14% [65] E. coli
C8-AP-dG 51% [66] Not mutagenic [66] Human
C8-AAF-dG 13% [66] Not mutagenic [66] Human
C8-AF-dG 97% [66] Not mutagenic [66] Human
AL-I-dA 100% (5% Rev3L-) [67] A>T 50% (Not mutagenic, Rev3L-) [67] Mouse
AL-II-dA 5% [63] A>T 22% [63] Mouse
BPDE-dG (40% Rev1-); (13% Rev3L-) [68] G>T 73%, G>A 12%; (G>T 32%, G>A 18%, Rev1-);(G>T 6%, Rev3L-) [68] Mouse
Crosslinked Lesion Bypass Efficiency Mutation Cell
ICL-RD 43% [69] 5′-G>T 3% [69] E. coli
ICL-R 38% [69] 5′-G>T 3% [69] E. coli
ICL-S 53% [69] 5′-G>T 3% [69] E. coli
AP-dG (dG strand) 38% (43% Pol η-), (13% Pol ι-),(2% Pol κ-), (5% Pol ζ-) [70] G>A 2-5%, G>T 1–2%, G>C 1% [70] Human
AP-dG (AP strand) 18% (25% Pol η-), (4% Pol ι-), (1%Pol κ-), (5% Pol ζ-) [70]
AP>T 74%, AP>C 10-20%, AP>G 4–6%, AP>A
1–2% [70] Human
1,2-GG-cis-DDP 11% [71]; 5% (30% SOS) [72] <0.25% (G>T 1.3%, SOS) [72] E. coli
1,2-AG-cis-DDP 22% (32% SOS) [72] <0.2% (A>T 4.4%, SOS) [72] E. coli
1,3-GTG-cis-DDP 13% (14% SOS) [72] <0.7% [72] E. coli
γ-HOPdG mediated
peptide crosslink G>T 5%, G>C 3% [20] Human
γ-HOPdA mediated
peptide crosslink Not mutagenic [20] Human
5fC mediated peptide
crosslink C>T 7%, C>G 1%, C del 2% [73] Human
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Table 1. Cont.
Other Nucleotide
Analog Bypass Efficiency Mutation Cell
H 5% [74] T>A 41%, T>C 5%, T>G 4%, −1 del 13% [74] E. coli
F 13% [74] T>A 9%, T>C 1%, T>G 1% [74] E. coli
L 20% [74] T>A 5% [74] E. coli
B 12% [74] T>A 24% [74] E. coli
I 10% [74] T>A 46%, T>C 1%, T>G 1%, −1 del 6% [74] E. coli
KP1212 128% [57] C>T 10% [57] E. coli
xG 11% (45% SOS) [75] G>A 95% [75] E. coli
xA 80% (108% SOS) [75] <1% [75] E. coli
xT 73% (102% SOS) [75] T>A 73% [75] E. coli
xC 29% (53% SOS) [75] C>A 10% [75] E. coli
α-dG 3% [76] G>A 60%, G>C 6% [76] E. coli
α-dA 20% [76] Not mutagenic [76] E. coli
α-dT 1% [76] Not mutagenic [76] E. coli
α-dC 1% [76] C>A 72% [76] E. coli
dxG 25% [77] Not mutagenic [77] E. coli
dxA 75% [77] A>G 10% [77] E. coli
dxT 150% [77] Not mutagenic [77] E. coli
dxC 125% (CXT), 175%(GXG) [77] Not mutagenic [77] E. coli
sG
98% [78] G>A 11% [78] E. coli
98% [79] G>A 8% [79] Human
S6mG
91% [78] G>A 94% [78] E. coli
95% [79] G>A 40% [79] Human
SO3HG 87% [78] G>A 77% [78] E. coli
2′-F-G 99% [8] Not mutagenic [8] E. coli
J 52% [60] Not mutagenic [60] Human
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2.1. Oxidative Biomarkers
All the structures of modifications covered in this section are displayed in Figure 2. 8-Oxo-7,8-
dihydro-2′-deoxyguanosine (8-oxo-G) is not a strong block to replication, demonstrating greater than
80% bypass efficiency in E. coli [28]. Its mutagenic pairing with A during replication in wild type
(WT) cells leads to a low amount of G>T mutation (3%) [28]. However, in MutY-cells (MutY: adenine
glycosylase in 8-oxo-G:A base excision repair), the G>T mutation increases to 44% [29]. 8-oxo-G causes
mainly G>T mutation with a frequency of 8% in human cells [28,29]. Thymidine glycol (Tg) is not
a replication block, and it is not mutagenic in E. coli; however, tandem lesions of 8-oxoG and Tg
are twice as effective as a single 8-oxo-G in blocking DNA replication, and the dual lesion is more
mutagenic than 8-oxo-G [38]. Fapy-dG (N-(2-deoxy-α,β-d-erythropentofuranosyl)-N-(2,6-diamino-4-
hydroxy-5-formamidopyrimidine)) strongly blocks replication by 60–70% in E. coli, but it is not very
mutagenic, providing less than 2% G>T mutation [31]. Fapy-dG causes 10% G>T mutation in human
cells [30]. 5-Guanidino-4-nitroimidazole (NI) strongly blocks replication (93%) in E. coli, giving mainly
G>T (22%) and G>A (19%) mutations, and some G>C (9%) mutation as well [32]. Oxaluric acid (Oa) is
toxic, blocking replication by 50%, causing nearly 100% G>T mutation in E. coli [28,31,34]. Oxazalone
(Oz) strongly blocks replication and is very mutagenic, causing 86% G>T mutation [28]. Cyanuric
acid lesion (Ca) blocks 35% replication in E. coli, and is very mutagenic with 95% G>T mutation [28].
Guanidinohydantoin (Gh) slightly blocks replication (25%), and it is highly mutagenic yielding 97%
G>C and 2% G>T mutation [34]. Two stable stereoisomers of spiroiminodihydantoin (Sp1 and Sp2)
are strong replication blocks (91%), and are both very mutagenic, causing mainly G>C (72% for Sp1
and 57% for Sp2) and G>T (27% for Sp1 and 41% for Sp2) mutations [34]. Urea lesion (Ur) is a strong
replication block (90%) causing 54% G>T, 35% G>C, and 9% G>A mutations [29,35]. Imidazolone
adduct (Iz) can be bypassed in E. coli with a 40% blockage in replication, essentially causing G>C
(88%) mutation, with some G>A (2%) and G>T (1%) mutations [32]. 8,5′-Cyclo-2′-deoxyguanosine
(cdG) is a strong replication block (89%) in E. coli, and knocking out pol V increases its replication
block; it is mutagenic and causes 20% G>A mutation [36]. The 5′ S-diastereomer of cyclo-dG (S-cdG)
also strongly blocks DNA replication (96%) in human cells, giving primarily G>T (35%) and G>A
(20%) mutations [37]. 8,5′-Cyclo-2′-deoxyadenosine (cdA) is 31% bypassed in E. coli, but the bypass
efficiency drops to 13% when pol V is removed from the cell [36]. It is mutagenic and causes A>T
(11%) mutation [36]. The 5′ S-diastereomer of cyclo-dA (S-cdA) strongly blocks replication in human
cells by 94% [37]. Knocking down pol η by siRNA decreases the bypass efficiency and mutagenicity of
S-cdA [37]. 5-Chlorocytosine (5-Cl-dC) blocks replication (25%), forming a low level of C>T mutation
(5%) in E. coli [39]. 5-Hydroxycytosine (5-OH-dC) is not mutagenic in E. coli [40]. 5-Hydroxyuracil
(5-OH-dU, derived from 5-OH-dC) is very mutagenic providing 83% C>T mutation in E. coli [40].
5,6-Dihydroxy-5,6-dihydrouracil (Ug) is also very mutagenic (80% C>T) in E. coli [40].
Tetrahydrofuran (THF) is a stable structural analog to the abasic site (AP site), which is not stable
and may lead to further damages to the DNA strand. THF strongly blocks replication (>95%) and
causes G>T (50%), G>C (26%), and G>A (7%) mutations; additionally, it causes 13% −1 frame shift
mutation [28,29,32,34,80].
2.2. Alkyl Biomarkers
All the structures of modifications covered in this section are displayed in Figure 3.
1-Methyldeoxyguanosine (m1G) is a strong replication block either with or without the repair
enzyme AlkB (85% and 97%); it mainly causes ~3% G>T mutation in WT E. coli, which increases
to more than 50% in AlkB- E. coli (AlkB: alkyl DNA adduct direct reversal of damage repair
protein) [9,33]. N2-methylguanine (m2G) weakly blocks replication by 10% in E. coli, there is no
significant change when knocking out either AlkB or DinB (DinB: DNA polymerase IV), and a small
amount of G>A mutation (3%) is seen [42]. N2-ethylguanine (e2G) does not block replication in E.
coli and causes a low amount of G>A mutation (2%); eliminating AlkB and DinB does not change
the replication bypass and mutagenicity significantly [42]. N2-carboxymethyl-2′-deoxyguanosine
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(N2-CMdG) and N2-(1-carboxyethyl)-2′-deoxyguanosine (N2-CEdG) do not block DNA replication
and are not mutagenic in WT mammalian cells; however, each of them causes G>A (23%) and G>T
(15%) mutations in mouse embryonic fibroblast (MEF) cells that are deficient in pol κ [43]. N2-CEdG
blocks replication in E. coli [44]. The R-N2-CEdG is a stronger replication block (61%) than S-N2-CEdG
(25%); however, neither of them are mutagenic [44]. N2-furfurylguanine (N2-FF-dG) does not block
replication in WT E. coli; however, it blocks replication about 72% in DinB- cells [42]. It is not very
mutagenic with or without DinB [42]. 2-Tetrahydrofuran-2-yl-methylguanine (N2-HF-dG) is similar
in structure to N2-FF-dG and strongly blocks replication (72%) only when DinB is knocked out, and
causes only 2% G>C mutation [42]. O6-methylguanine (O6mG) is very mutagenic and leads to almost
100% G>A mutation in Ada/Ogt/UvrB triple knockout E. coli (Ada/Ogt: alkyl DNA adduct direct
reversal of damage repair protein; UvrB: nucleotide excision repair) [45,46]. N-Nitroso compounds
induce DNA lesions: O6-pyridyloxobutyl-dG (O6-POB-dG),O6-pyridylhydroxybutyl-dG (O6-PHB-dG),
O6-carboxymethyl-dG (O6-CMdG), which have two structural analogs: O6-aminocarbonylmethyl-dG
(O6-ACM-dG) and O6-hydroxyethyl-dG (O6-HOEt-dG) [47]. O6-POB-dG slightly blocks DNA
replication and induces G>A (90%) transition and G>T (2.5%) transversion in E. coli [47]. O6-PHB-dG
is a moderate impediment to DNA replication and causes G>A (95%) mutation exclusively in E.
coli [47]. O6-CMdG strongly inhibits replication in E. coli, but causes moderate G>A (10%) mutation [47].
O6-ACM-dG and O6-HOEt-dG are two analogs of O6-CM-dG. Both O6-ACM-dG (2% bypass) and
O6-HOEt-dG (15% bypass) strongly block DNA replication [47]. They also induce G>A mutation
with 30% and 40% frequencies, respectively [47]. Major acrolein-dG adducts include 8α and 8β
isomers of 3H-8-hydroxy-3-(β-D-2′-deoxyribofuranosyl)-5,6,7,8-tetrahydropyrido[3,2-a]purine-9-one
(γ-OH-PdG), 6α and 6β isomers (α-OH-PdG), and 1,N2-(1,3-propano)-2′-deoxyguanosine (PdG) [12].
The bypass efficiency for γ-OH-PdG is 73% compared to dG control in human cells, and γ-OH-PdG is
not very mutagenic (<1%) [12]. α-OH-PdG strongly blocks DNA replication with a bypass efficiency of
17% in human cells and it causes G>T (11%) mutation [13]. PdG strongly blocks replication in human
cells and mainly causes 6% G>T mutation [12]. Most of the derivatives of PdG moderately block
DNA replication in human cells and cause mainly G>T mutation (2–8%) [81]. 1,N2-ethenoguanine
(1,N2-eG) is a strong replication blocker (96%) in E. coli and causes G>A and G>T mutation by 6%
for both, plus a small amount of G>C (2%) mutation; it also causes −1 and −2 frame shift mutations
(5%), and knocking out AlkB leads to higher replication block and almost doubles the mutagenicity [8].
2′-Fluoro-N2,3-ε-2′-deoxyarabinoguanosine (2′-F-N2,3-eG), a stable analog of N2,3-ethenoguanine
(N2,3-eG), blocks replication by 79%, and causes 30% G>A mutation in E. coli, with AlkB having no
significant influence in its replication bypass and mutagenicity [8].
1-Methyldeoxyadenosine (m1A) strongly blocks replication in AlkB- E. coli (88%), but it is not
very mutagenic, causing <1% A>T mutation; m1A does not block replication in AlkB+ E. coli cells [9].
1,N6-ethenoadenine (eA) weakly blocks replication by 4% in WT E. coli, but significantly blocks
replication (95%) when AlkB is knocked out; likewise, eA is not mutagenic in WT E. coli, but shows
strong mutagenicity in AlkB- cells (25% A>T mutation) [33,49]. Bypass efficiency of eA in human
cells is 17% [50]. 1,N6-ethanoadenine (EA) does not block replication in WT E. coli, but strongly
blocks replication by 86% when AlkB is removed; it is not very mutagenic in either WT or AlkB- cells,
causing only 2% A>C mutations [49]. N6-carboxymethyl-2′-deoxyadenosine (N6-CMdA) minimally
blocks replication in E. coli and is not mutagenic [36]. S-N6-HB-dA (HB = 2-hydroxy-3-buten-1-yl)
and R,R-N6,N6-DHB-dA (DHB = 2,3-dihydroxybutan-1,4-diyl) do not block DNA replication and
are not mutagenic in E. coli [51]. S,S-N6,N6-DHB-dA moderately inhibits replication with a 60%
bypass efficiency, and causes minimal 1% A>G mutation [51]. R,S-1,N6-γ-HMHP-dA (HMHP =
2-hydroxy-3-hydroxymethylpropan-1,3-diyl) strongly inhibits DNA replication but causes only 2%
A>T mutation [51].
O2-Methylthymidine (O2-Me-dT) can be bypassed by 55% in human cells and mainly causes T>A
mutation (56%) [53]. O2-[4-(3-pyridyl-4-oxobut-1-yl]thymidine (O2-POB-dT) exhibits genotoxicity
showing 26% bypass efficiency and is mutagenic with 47% T>A transversion [53]. Both O2-Me-dT
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and O2-POB-dT strongly block DNA replication in E. coli (95% and 97%) [54]. O2-Me-dT induces
10% T>A and 10% T>G mutations [54]. O2-POB-dT induces 38% T>G and 12% T>A mutations [54].
O2-Ethylthymidine (O2-EtdT) is a strong replication block (79%) in E. coli, and knocking out pol IV
increases the blocking activity, while knocking out pol V increases the replication block even more [55].
It is very mutagenic and forms T>C (35%), T>A (15%), and T>G (5%) mutations, and mutation
frequency drops when pol V is knocked out [55]. The bypass efficiency of O2-dT alkyl adducts in
E. coli depends on the size of the alkyl lesion [82]. More than 20% of adducts can be bypassed during
replication for ethyl and methyl substitutions, but less than 10% can be bypassed for propyl, and less
than 5% for butyl adducts, with the major mutation type being T>C point mutation [82]. O2-alkyldT
lesions strongly inhibit DNA replication (40–85%) in mammalian cells [52]. The blockage effect increases
with the size and branching of the alkyl groups [52]. These lesions cause T>A and T>G mutations [52].
3-Methyldeoxythymidine (m3T) strongly blocks replication in E. coli by 94% and is very mutagenic,
generating mainly T>A (32%) transversion mutation; eliminating AlkB slightly increases its replication
blocking power and mutagenicity [9]. N3-Ethylthymidine (N3-EtdT) strongly blocks replication by 83%
in E. coli, and knocking out pol V or pol IV increases its blocking activity; it is very mutagenic causing
T>A (21%), T>C (15%) and T>G (3%) mutations, and removing pol V eliminates the mutagenicity of
this adduct [55]. N3-carboxymethylthymidine (N3-CMdT) strongly blocks replication by 45% in E. coli,
with the major mutation being T>A (66%); and knocking out pol V slightly increases the mutation
rate; however, knocking out pol IV decreases the mutation rate [36]. O4-carboxymethylthymidine
(O4-CMdT) is a strong replication block (51%) and very mutagenic, causing 86% T>C mutation [36].
N3-CMdT, O4-CMdT and O6-carboxymethyl-dG (O6-CMdG) moderately block DNA replication in
human cells [48]. N3-CMdT causes T>A (81%) mutation; O4-CMdT causes T>C (68%) mutation;
O6-CMdG causes G>A (6.4%) mutation; neither N6-CMdA nor N4-CMdC block replication or induce
mutation [48]. O4-Ethylthymidine (O4-EtdT) does not strongly block replication (24%) in WT E. coli,
but it cannot be efficiently bypassed in pol II/IV/V triple knock out cells [55]. The major mutation of
O4-EtdT is T>C (84%) transition; however, it does not cause mutations in E. coli lacking pol V [55].
O4-Alkylthymidine (O4-alkyldT) lesions moderately block DNA replication in human cells; pol ι and
pol ζ promote the bypass of all O4-alkyldT lesions except O4-MedT [56]. The O4-alkyldT lesions induce
only T>C transition mutations in cells [56].
3-Methyldeoxycytidine (m3C) has been demonstrated to strongly block replication (>90%) and
generate mainly C to T (50%) and C to A mutations (30%) in the AlkB- E. coli cell [9]. However, the
lesion is not mutagenic and not blocked by the replicative polymerases in the WT (AlkB+) cell [9].
3-Ethyldeoxycytidine (e3C) does not block replication in E. coli; however, it dramatically blocks
replication when knocking out AlkB (91%) [9]. e3C causes 17% C>T, 11% C>A, and 2% C>G mutations
in AlkB- E. coli, but is not mutagenic in WT cells [9]. The m3C, e3C, and m1A lesions presumably have
their methyl or ethyl groups removed by AlkB’s direct reversal of DNA alkyl damage mechanism prior
to encountering the DNA polymerase [9]. N4-carboxymethyl-2′-deoxycytidine (N4-CMdC) weakly
blocks replication (17%) and is not mutagenic in E. coli [36]. 5-Methylcytosine (5mC) and its derivatives
5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) neither block
replication nor cause mutation in E. coli [39,59]. 5mC also does not block replication in human cells,
but there are some blockades of 5hmC (5%), 5fC (25%), and 5caC (28%) towards DNA replication in
human cells [58]. 3,N4-ethenocytosine (eC) is a toxic adduct, which strongly blocks replication (76%)
and leads to mutation with a pattern of dominant C>A (24%) and less C>T (11%) mutations in WT
E. coli; in AlkB- cells, the blockage of replication increases to 87% and mutagenicity rises up to 49%
C>A and 31% C>T mutations [33]. Lipid peroxidation-derived product 4-oxo-2(E)-nonenal reacts
with dG, dA, and dC in DNA to form heptanone (H)-etheno (e) adducts [50]. H-edC shows strong
DNA replication blocking in both E. coli (99%) and human cells (90%) [50]. It causes mainly C>G (40%)
mutation in E. coli; however, mostly C>A (60%) and C>T (32%) mutations are seen in human cells [50].
5-Hydroxymethyluracil (5hmU) blocks replication by 20%, but it is not mutagenic in human
cells [60]. The Sp alkyl phosphotriester (Sp-alkyl-PTE) lesions display comparable replication
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bypass efficiency to unmodified DNA in E. coli; Sp-Me-PTE is mutagenic causing TT>GT (50%)
and TT>GC (15%) mutations [61]. In contrast, Rp-alkyl-PTEs block DNA replication (30–70%) but are
not mutagenic [61]. Interestingly, nPr- and nBu-PTEs exhibit higher bypass efficiencies than Me- and
Et-PTEs [61].
2.3. Bulky Lesions
All the structures of modifications covered in this section are displayed in Figure 4.
N-(deoxyguanosin-8-yl)-1-aminopyrene (C8-AP-dG) moderately blocks DNA replication in human
cells [66]. N-acetyl-2-aminofluorene (C8-AAF-dG) strongly blocks replication [66]. 2-Aminofluorene
(C8-AF-dG) slightly blocks replication [66]. All three adducts can be nearly bypassed in error
free manner [66]. Aristolochic acids I and II (AA-I, AA-II) are found in all Aristolochia species
and generate the aristolactam (AL) metabolite for forming DNA adducts with dA and dG. Both
AL-II-dA and AL-II-dG strongly block DNA replication in MEF cells [63]. AL-II-dA causes 22% A>T
mutation and AL-II-dG causes 9% G>T transversion [63]. Knocking out the rev3L gene dramatically
suppresses bypass of AL-I-dA in MEF cells and abolishes A>T transversion [67]. Benzo[a]pyrene
(BP)-7,8-diol-9,10-epoxide-N2-deoxyguanosine (BPDE-dG) is an adduct formed by benzo[a]pyrene; it
predominantly miscodes with G>T (73%) and G>A (12%) mutations in WT MEF cells [68]. Knocking
out rev1 gene decreases the bypass efficiency of BPDE-dG to 40% and changes the mutation frequency
to 32% G>T and 18% G>A [68]. Knocking out the rev3L gene significantly decreases the bypass
efficiency to 13% and decreases the mutation to 6% G>T [68]. Mitomycin C (MC) generates dG-N2-MC
and dG-N2-2,7-Diaminomitosene (DAM) adducts, which can be bypassed 38% and 27% in human
cells, respectively [62]. The major type of mutation is G>T mutation (18% for dG-N2-MC and 10%
for dG-N2-2,7-DAM) [62]. Aflatoxin B1-N7-dG adduct (AFB1-N7-dG) is weakly mutagenic in E. coli,
causing 1.5% G>T mutation [64]; and its FAPY adduct causes 14% G>T mutation [65].
2.4. Crosslinked Lesions
All the structures of modifications covered in this section are displayed in Figure 4. N2-guanine
-N2-guanine interstrand crosslinks (ICLs), 3-(2-deoxyribos-1-yl)-5,6,7,8-(N2-deoxyguanosyl)-6(either R
or S)-methylpyrimido[1,2-R]purine-10(3H)-one is a product induced by acetaldehyde/crotonaldehyde [69].
ICL-S and ICL-R moderately inhibit DNA replication in WT E. coli; however, their replication blocking
effects increase in uvr- E. coli cells [69]. ICL-Rd is a moderate block in WT E. coli, but it almost
completely blocks replication in uvr- cells [69]. All three lesions are weakly mutagenic in E. coli
causing exclusively 5′-G>T (3%) transversions; no mutation is observed at the 3′-G site [69]. Similar
mutations generated by these lesions are seen in human cells, except ICL-S has a slightly higher
mutation frequency (6%) [69]. The crosslinks formed by cis-diaminedichloroplatinum (II) (cis-DDP,
cisplatin) between two guanines or adenine-guanine strongly block DNA replication in E. coli, but they
are not very mutagenic [72]. 5-Formylcytosine mediated peptide crosslink causes 7% C>T and 1% C>G
mutation and 2% C deletion [73]. γ-Hydroxypropanodeoxyguanosine (γ-HOPdG) mediated crosslink
between peptide and guanine is mutagenic, causing 5% G>T and 3% G>C mutations; however, the
crosslink between peptide and γ-hydroxypropanodeoxyadenine (γ-HOPdA) is not mutagenic [20].
2.5. Other Nucleotide Analogs
All the structures of modifications covered in this section are displayed in Figure 5. A series
of unnatural analogs of thymine (T) was developed by the Kool group to probe the biological
requirements for DNA polymerases [74]. 3-Toluene-1-β-D-deoxyriboside (H) strongly blocks
replication (95%) and is very mutagenic causing T>A (41%), T>C (5%), and T>G (4%) point
mutations and −1 frame shift mutation (13%). 2,4-Difluoro-5-toluene-1-β-D-deoxyriboside (F)
strongly blocks replication (87%) and is mutagenic causing T>A (9%), T>C (1%), and T>G (1%)
mutations. 2,4-Dichloro-5-toluene-1-β-D-deoxyriboside (L) strongly blocks replication (80%) and
is slightly mutagenic causing T>A (5%) mutation. 2,4-Dibromo-5-toluene-1-β-D-deoxyriboside
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(B) strongly blocks replication (88%) and is mutagenic, causing T>A (24%) mutation.
2,4-Diiodo-5-toluene-1-β-D-deoxyriboside (I) strongly blocks replication (90%) and is very mutagenic
causing T>A (46%), T>C (1%), and T>G (1%) point mutations and−1 frame shift mutation (6%) [74]. xG
is an ‘expanded base’ of dG (retaining the hydrogen-bonding face), which strongly blocks replication
(89%) and is very mutagenic, causing G>A (95%) mutation [75]. xA (expanded A) weakly blocks
replication (20%) and is not mutagenic; xT (expanded T) weakly blocks replication (27%), but is very
mutagenic, causing T>A (73%) mutation; xC (expanded dC) strongly blocks replication (71%) and is
mutagenic, causing C>A (10%) mutation [75].
The α-anomer of deoxynucleosides (α-dN) can be generated as a result of hydroxyl radical attack
on deoxyribose [76]. All α-dNs except α-dA strongly block replication in E. coli [76]. α-dC blocks
almost 99% replication and causes 72% C>A mutation [76]. α-dG also strongly blocks replication and
causes 60% G>A mutation [76]. α-dT blocks almost 99% replication but it is not mutagenic in WT
E. coli [76]. α-dA is not mutagenic [76]. The anticancer agent 6-thioguanine (sG) and its derivative
S6-methylthioguanine (S6mG) do not block replication strongly in both E. coli and human cells [78]. sG
causes 11% G>A mutation and S6mG causes 94% G>A mutation in E. coli [78]. sG is less mutagenic
(8%) than S6mG (40%) in human cells as well [78]. Guanine-S6-sulfonic acid (SO3HG) is another
derivative of sG [78]. It is not a strong replication block in E. coli, but it is very mutagenic, causing
77% G>A mutation [78]. The anti-HIV drug KP1212 is an analog of deoxycytidine [57]. It does
not block replication in E. coli, but is mutagenic causing 10% C>T mutation [57]. Among the four
2′-deoxyxylonucleosides (xN), only xA and xG exhibit a replication block in E. coli [77]. xA is the only
mutagenic lesion among the four and causes 10% A>G mutation [77]. Base J strongly blocks replication
by 48%, but is not mutagenic in human cells [60].
3. Perspectives
In this review, we survey the biological effects of various DNA lesions or biomarkers studied
by the shuttle vector techniques, allowing one to gain insight into how DNA damage or other
chemically defined nucleobases are processed by polymerases and repair machinery in a natural cellular
environment under physiological conditions. Among the new methods that have been developed
or applied in the last decade, MS-based strategies and NGS methods have been demonstrated to
be efficient for analyzing the lesion’s biological outcomes. LC-MS-based methods are sensitive and
accurate for quantifying the degree of lesion bypass and point mutations [4,5]. NGS techniques allow
for a large-scale population analysis on many samples at the same time and provide information on a
genomic perspective [4,8]. Another possible direction for using vectors as probes to analyze biomarkers
is to study the mutational spectrum or mutational signature of a certain chemical or damaging
agent [83–86]. LC-MS- and NGS-based analyses not only consider the biological consequences at the
lesion site, but also incorporate information from the neighboring bases, such as one or two nucleotides
next to the lesion site from both the 5′ and 3′ direction. An oligonucleotide containing the modified
base can be made surrounded by nearest (and next-to nearest) randomized bases and ligated into a
shuttle vector. While cellular analysis may pull out a hotspot consensus sequence for poor repair and/or
mutagenic replication, this will not answer the primary question of contextual bias in adduct formation.
Shuttle vector systems whereby the vector is treated with the chemical to be assessed, followed by
quantification of adduct type and amount, and transfection into isogenic cells of varying repair and/or
replication backgrounds may tease apart the contribution of local sequence environment to adduct
formation, repair, and replication. Such vectors were used over a decade ago [87], and coupled with
NGS throughput and bioinformatics, may provide enough reads to make statistically significant claims.
Shuttle vectors are currently, to our knowledge, mainly DNA-based; however, one can envision use
of RNA-based vectors to study the effect of modified RNA bases on cellular processes such as viral
replication, translation, reverse transcription, and possibly even repair. While the role of DNA damage
in toxicology focuses mainly on the direct adduction of chemical damage to DNA, pool mutagenesis
has often been overlooked, and it would be interesting to leverage shuttle vector techniques to study
Toxics 2019, 7, 36 14 of 18
the incorporation of modified bases from the nucleotide pool in the form of damaged DNA or from
DNA-based therapeutics.
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